CA2214451A1 - Systeme d'expression conditionnel - Google Patents
Systeme d'expression conditionnel Download PDFInfo
- Publication number
- CA2214451A1 CA2214451A1 CA002214451A CA2214451A CA2214451A1 CA 2214451 A1 CA2214451 A1 CA 2214451A1 CA 002214451 A CA002214451 A CA 002214451A CA 2214451 A CA2214451 A CA 2214451A CA 2214451 A1 CA2214451 A1 CA 2214451A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- transactivator
- domain
- molecule
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9503841A FR2732348B1 (fr) | 1995-03-31 | 1995-03-31 | Systeme d'expression conditionnel |
FR9503841 | 1995-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2214451A1 true CA2214451A1 (fr) | 1996-10-03 |
Family
ID=9477639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002214451A Abandoned CA2214451A1 (fr) | 1995-03-31 | 1996-03-29 | Systeme d'expression conditionnel |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0817845A1 (ko) |
JP (1) | JPH11503011A (ko) |
KR (1) | KR19980703439A (ko) |
AU (1) | AU716748B2 (ko) |
BR (1) | BR9607928A (ko) |
CA (1) | CA2214451A1 (ko) |
CZ (1) | CZ308097A3 (ko) |
FR (1) | FR2732348B1 (ko) |
HU (1) | HUP9801221A3 (ko) |
IL (1) | IL117713A0 (ko) |
NO (1) | NO974449D0 (ko) |
SK (1) | SK131197A3 (ko) |
TW (1) | TW496873B (ko) |
WO (1) | WO1996030512A1 (ko) |
ZA (1) | ZA962506B (ko) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0872552A1 (en) * | 1997-04-15 | 1998-10-21 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin |
EP0878546A1 (en) * | 1997-04-15 | 1998-11-18 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin |
FR2775984B1 (fr) | 1998-03-11 | 2006-09-15 | Bioscreen Therapeutics Sa | Criblage differentiel qualitatif |
US6881571B1 (en) | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
FR2755144B1 (fr) * | 1996-10-29 | 1998-11-27 | Rhone Poulenc Rorer Sa | Fragments d'anticorps a chaine unique anti-p53 et utilisation |
US7276488B2 (en) | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
WO1998055607A2 (en) * | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
US6479653B1 (en) * | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
EP1040201A4 (en) * | 1997-11-28 | 2001-11-21 | Invitrogen Corp | SINGLE CHAIN MONOCLONAL ANTIBODY FUSION AGENTS THAT REGULATE IN VIVO TRANSCRIPTION |
FR2782732A1 (fr) * | 1998-08-28 | 2000-03-03 | Transgene Sa | Systeme d'expression inductible |
US7691370B2 (en) | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
EP1242456B1 (en) | 1999-11-18 | 2008-10-15 | Oxford Biomedica (UK) Limited | Scfv antibodies against disease associated molecules |
GB0015090D0 (en) * | 2000-06-20 | 2000-08-09 | Implyx Ltd | Gene-activating conjugates |
WO2003045415A2 (en) * | 2001-11-26 | 2003-06-05 | University Health Network | Self-assembling p53 peptides as gene delivery vehicles |
AU2003229998A1 (en) | 2002-05-10 | 2003-11-11 | Medical Research Council | Activation induced deaminase (aid) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2752788B2 (ja) * | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
CA2143326A1 (en) * | 1992-08-26 | 1994-03-03 | Guerard Byrne | Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals |
GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
US5866755A (en) * | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
US5650298A (en) * | 1993-06-14 | 1997-07-22 | Basf Aktiengesellschaft | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
FR2710074B1 (fr) * | 1993-09-15 | 1995-12-08 | Rhone Poulenc Rorer Sa | Gène GRB3-3, ses variants et leurs utilisations. |
-
1995
- 1995-03-31 FR FR9503841A patent/FR2732348B1/fr not_active Expired - Fee Related
-
1996
- 1996-03-28 IL IL11771396A patent/IL117713A0/xx unknown
- 1996-03-28 ZA ZA962506A patent/ZA962506B/xx unknown
- 1996-03-28 TW TW085103937A patent/TW496873B/zh active
- 1996-03-29 AU AU54020/96A patent/AU716748B2/en not_active Ceased
- 1996-03-29 SK SK1311-97A patent/SK131197A3/sk unknown
- 1996-03-29 BR BR9607928A patent/BR9607928A/pt not_active Application Discontinuation
- 1996-03-29 EP EP96911000A patent/EP0817845A1/fr not_active Withdrawn
- 1996-03-29 CA CA002214451A patent/CA2214451A1/fr not_active Abandoned
- 1996-03-29 JP JP8529022A patent/JPH11503011A/ja not_active Ceased
- 1996-03-29 CZ CZ973080A patent/CZ308097A3/cs unknown
- 1996-03-29 HU HU9801221A patent/HUP9801221A3/hu unknown
- 1996-03-29 KR KR1019970706843A patent/KR19980703439A/ko not_active Application Discontinuation
- 1996-03-29 WO PCT/FR1996/000477 patent/WO1996030512A1/fr not_active Application Discontinuation
-
1997
- 1997-09-26 NO NO974449A patent/NO974449D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR9607928A (pt) | 1998-06-09 |
MX9706928A (es) | 1997-11-29 |
AU5402096A (en) | 1996-10-16 |
SK131197A3 (en) | 1998-05-06 |
HUP9801221A2 (hu) | 1998-08-28 |
FR2732348B1 (fr) | 1997-04-30 |
AU716748B2 (en) | 2000-03-02 |
NO974449L (no) | 1997-09-26 |
HUP9801221A3 (en) | 1999-09-28 |
EP0817845A1 (fr) | 1998-01-14 |
WO1996030512A1 (fr) | 1996-10-03 |
CZ308097A3 (cs) | 1998-01-14 |
TW496873B (en) | 2002-08-01 |
ZA962506B (en) | 1996-10-01 |
KR19980703439A (ko) | 1998-11-05 |
NO974449D0 (no) | 1997-09-26 |
IL117713A0 (en) | 1996-07-23 |
JPH11503011A (ja) | 1999-03-23 |
FR2732348A1 (fr) | 1996-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2214451A1 (fr) | Systeme d'expression conditionnel | |
EP0848720B1 (fr) | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers | |
FR2722208A1 (fr) | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique | |
FR2736915A1 (fr) | Variants de la proteine p53 et utilisations therapeutiques | |
EP1049775B1 (fr) | Proteine humaine btrcp | |
CA2250099A1 (fr) | Sequences en amont du gene sm22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires | |
WO1998021327A1 (fr) | Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes | |
CA2252529A1 (fr) | Systeme d'expression derive du gene de la tyrosine hydroxylase | |
WO1996038556A2 (fr) | Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse | |
EP0941243A1 (fr) | Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations | |
FR2720068A1 (fr) | Protéines d'interaction avec la protéine Nef du virus HIV1, séquences d'acides nucléiques codant pour ces protéines et leur utilisation pour le criblage d'agents anti-viraux anti-HIV. | |
MXPA97006928A (es) | Sistema de expresion condicional | |
CA2343922A1 (fr) | Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire | |
Isserlin | Syntrophin expression and interacting protein partners in the central nervous system | |
FR2783839A1 (fr) | Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |